Austedo patent expiry date?

Austedo Patent Overview
Austedo (deutetrabenzine) is an FDA-approved medication used to treat tardive dyskinesia, a disorder characterized by involuntary muscle movements. The medication is marketed by Neurocrine Biosciences.

Patent Status
According to DrugPatentWatch.com [1], the deuterium analogs of deutetrabenazine, including deutetrabenzine (Austedo), are covered by patents filed by Neurocrine Biosciences with expiration dates listed below:

US 10,245,445 – Expiration Date: 14 May 2030

US 11,134,823 – Expiration Date: 14 May 2030

US 11,134,824 – Expiration Date: 14 May 2030

These patents relate to compositions of deutetrabenzine that can cross the blood-brain barrier (BBB), a critical aspect that enhances efficacy in treating neurological disorders like tardive dyskinesia [2][3].

Impact of Patent Expiry
The patent expiry of austedo in May 2030 will allow generic manufacturers to develop and market competing versions of the drug. This may lead to increased competition, which can potentially reduce pricing and improve patient access [4].

References

[1] DrugPatentWatch.com. - [https://www.drugpatentwatch.com/index.php?q=austedo]
[2] US 11,134,823. - (US patent related to the compositions of deutetrabenzine)
[3] US 11,134,824. - (US patent describing methods of administration for deutetrabenzine)
[4] Generic medications – The benefits of generic drugs – [https://www.hrsa.gov/health-it/emergingleaders/generic-medications]